E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determined the maximum tolerated dose (MTD), safety and
tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered
continually twice daily in combination with carboplatin and paclitaxel to patients with
advanced or metastatic non-small cell lung cancer.